Radiation Oncology

Table 1 Patient demographic and clinical characteristics before and after PSM

From: Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients

	Before PSM				After PSM
	CCRT	CCRT + AC	X2	p	CCRT	CCRT + AC	X2	p
Sex			1.081	0.298	99	99	0.033	0.855
Male	90	111			81	80
Female	23	20			18	19
Age			1.217	0.270			0.342	0.559
< 60	43	59			40	36
≥ 60	70	72			59	63
ECOG scoring			0.401	0.527			0.082	0.775
0	61	76			54	56
1–2	52	55			45	43
Tumor location			0.489	0.921			0.416	0.937
Cervical	9	10			9	10
Up	53	62			45	48
Middle	35	44			32	28
Down	16	15			13	13
Clinical stage			6.334	0.042			0.617	0.735
II	19	14			16	13
III	51	80			48	53
IVA	43	37			35	33
T stage			1.576	0.455			0.807	0.668
2	21	17			18	15
3	69	83			62	68
4	23	31			19	16
N stage			3.062	0.382			0.527	0.913
0	18	27			17	15
1	50	65			45	50
2	39	35			34	31
3	6	4			3	3
MacroType			1.044	0.791			1.275	0.735
Fungating	27	26			23	24
Ulcer	35	41			34	28
Medulla	33	45			25	31
Constrictive	18	19			17	16
CT regimen			1.885	0.170			0.081	0.775
PF	66	65			53	55
TP	47	66			46	44
Radiation dose			0.118	0.731			0.028	0.867
< 59.4 Gy	28	30			23	24
≥ 59.4 Gy	85	101			76	75
Target delineation			1.942	0.163			0.081	0.776
IFI	61	59			52	50
ENI	52	72			47	49
Short-term response			0.410	0.522			0.020	0.887
Good	65	70			53	54
Poor	48	61			46	45

PSM propensity score matching, ECOG Eastern Cooperative Oncology Group

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com